DESTINY-PanTumor02: The ADC trastuzumab deruxtecan (T-DXd) showed activity in HER2-expressing solid tumors.

Trastuzumab deruxtecan (T-DXd) is a HER2-targeted antibody-drug conjugate (ADC) that consists of the monoclonal antibody trastuzumab and the anticancer drug deruxtecan. T-DXd works by binding to HER2 and delivering deruxtecan to tumor cells, killing the tumor cells. In the DESTINY-PanTumor02 trial, trastuzumab deruxtecan (T-DXd) was used to treat patients with advanced solid tumors that were HER2-positive, including biliary tract, bladder, cervical, endometrial, ovarian, pancreatic, or other cancers. The study results showed that T-DXd significantly extended patients' progression-free survival (PFS) and overall survival (OS). In all patients, TDx-d's median PFS was 6.9 months, and the median OS was 13.4 months. In addition, TDx-d's objective response rate (ORR) in these patients was 37.1%, with a median duration of response (DoR) of 11.3 months. Based on these results, TDx-d has the potential to change the course of disease for patients with advanced HER2-positive cancers who have limited treatment options. These results offer new hope for TDx-d in the treatment of HER2-positive cancers. Trastuzumab deruxtecan is currently approved for the treatment of HER2-positive breast cancer, gastric cancer, and esophageal cancer in the US.

‍

Ref: J Clin Oncol. 2023 Oct 23:JCO2302005.